Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › VIJAYA

VIJAYA

Vijaya Diagnostic Centre Limited
Small-capPharma ↗

What the six lenses say about VIJAYA — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1497.5
2026-09-08
VWAP · 1Y anchor
₹1180
+26.9% from VWAP
P/E · TTM
89.0×
TTM EPS ₹16.8
52-week range
97%
position low→high
RSI(14)
58
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How VIJAYA’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD790›

The actual numbers

Price vs VWAP (1y)+26.9%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+22.7%
Price vs 50-EMA+5.8%
RSI(14)58
RS vs Nifty 500 · 3M+10.1%
RS vs sector · 3M+4.1%
52-week range97%
Volume vs 30d avg0.38×
Volume vs 60d avg0.30×
ATR(14) · volatility49.6
Bollinger width · vol contraction0.056
FundamentalD1081›

The actual numbers

Return on equity (ROE)19.7%
Return on capital (ROCE)21.3%
Operating margin32.6%
Net margin21.3%
Revenue growth · YoY+19.5%
EPS growth · YoY+20.5%
Debt / equity0.44×

Full 8-quarter history in the financials table below.

ValuationD10›

The actual numbers

P/E (TTM)89.0×
TTM EPS₹16.8
52-week range97%
CatalystD537›

The actual numbers

Earnings & momentum37
Capital actions18
Governance79

Every filing in the corporate-announcements panel below.

FlowD450›

The actual numbers

Promoter holding52.5%
Delivery · 30d avg45.7%
Up/down-day asymmetry-1.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D7 + D4 ) ÷ 2 = 5.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
86
Conviction score 86/100 · avg-decile strength 5.5/10
Conviction score86/100›
TechnicalD7›
FundamentalD10›
ValuationD1›
CatalystD5›
FlowD4›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.8pp
-0.1pp
+12.8pp
+11.7pp
+59.3pp
+39.3pp
Nifty 500
Broad-market baseline
+0.7pp
-0.1pp
+11.7pp
+10.1pp
+53.6pp
+34.1pp
Sector
Own-sector index
—
—
+8.9pp
+4.1pp
+40.4pp
+13.3pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

VIJAYA daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1497.50+4.30

Relative strength

RS vs baseline · rebased to 100

VIJAYA ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
165.28+1.17

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)156183169173188202205219
↳ change QoQ—+17.1%-7.6%+2.4%+8.7%+7.4%+1.5%+6.8%
EBITDA (₹cr)6580726974828696
EBITDA margin41.5%44.0%42.5%39.9%39.4%40.6%41.9%43.8%
PAT (₹cr)3242353539434348
↳ change QoQ—+33.7%-16.2%-0.8%+11.4%+10.3%+0.0%+11.6%
Net margin20.2%23.0%20.9%20.2%20.7%21.3%21.0%21.9%
EPS (₹)3.064.093.423.403.764.214.204.66
D/E————————
YoY growth · Mar '26Revenue +26.6% YoYPAT +37.1% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 2 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Sep '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Sep '26
    LOWgovernance
    Change in Management
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    LOWgovernance
    Change in Company Secretary/Compliance Officer
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    MEDIUMgovernance
    Resignation
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    MEDIUMgovernance
    Resignation of Director/KMP/SMP
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Aug '26
    LOWgovernance
    Change in Management
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Aug '26
    MEDIUMgovernance
    Change in Director(s)
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Aug '26
    MEDIUMgovernance
    Cessation
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds VIJAYA

Mutual funds holding VIJAYA (10)

FundWeightAUM ₹crGrade
Nippon India Multi Cap Bns0.73%55,587
Nippon India Multi Cap Gr0.73%55,587
Nippon India Multi Cap Dir Bns0.73%55,587
HDFC Small Cap Gr1.46%41,679
Axis Small Cap Fund Reg Gr0.92%30,089
ICICI Pru Flexicap Reg Gr0.80%24,100
Kotak Small Cap Reg Gr3.87%18,933
HSBC Small Cap Fund Reg Gr1.68%17,784
Axis Multicap Reg Gr0.52%10,973
Nippon India Pharma Bns2.42%9,279

ETFs holding VIJAYA (0)

No tracked ETF holds VIJAYA ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma